NMPA granted conditional approval for a drug on August 1, 2026, coinciding with the presentation of clinical trial data at ESMO.
2 reports, 1 independent
Updated Aug 28
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
NMPA granted conditional approval for a drug on August 1, 2026, coinciding with the presentation of clinical trial data at ESMO.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
European Society for Medical Oncology
Professional organisation
Related events
- Hengrui Pharma and Guangdong Provincial People's Hospital presented research findings at the ESMO Congress on October 20, 2026.
- Study results were presented by Tempus and Pfizer at the ESMO Congress, focusing on ongoing collaboration regarding diagnostic barriers.
- Researchers presented Phase 3 clinical data at the European Society for Medical Oncology (ESMO) Congress on September 21, 2026.
- AstraZeneca presented trial results for its IMFINZI cancer treatment at the European Society for Medical Oncology (ESMO) Congress in Madrid.
- ORIC Pharmaceuticals presented clinical trial data at a medical oncology meeting.